Join
Live feed
·
PRReleasevia Quantisnow
bioAffinity Technologies Inc. logo

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

ByQuantisnow·Wall Street's wire, on your screen.
BIAF· bioAffinity Technologies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIAF (bioAffinity Technologies Inc.) and more on Quantisnow.